ACAD vs AXSM
ACAD: Acadia Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for CNS disorders and rare diseases. AXSM: A fully integrated biopharmaceutical company developing innovative CNS treatments, with three FDA-approved commercial products and a deep pipeline of novel candidates.
Side-by-side fundamentals
| Metric | ACAD | AXSM | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $24.96 | $239.62 | |
| Market cap as of 2026-07-23 | $4.4B | $12.3B | |
| P/E as of 2026-07-23 | 11.59 | n/a | |
| PEG as of 2026-07-23 | -5.27 | 2.51 | ACAD lower |
| Net margin as of 2026-07-23 | +34.3% | -26.6% | ACAD higher |
| Gross margin as of 2026-07-23 | +91.5% | +92.6% | AXSM higher |
| Operating margin as of 2026-07-23 | +7.4% | -25.9% | ACAD higher |
| ROE as of 2026-07-23 | +35.6% | -260.0% | ACAD higher |
| ROA as of 2026-07-23 | +26.2% | -27.8% | ACAD higher |
| Debt / equity as of 2026-07-23 | 0.00 | 3.61 | ACAD lower |
| Revenue growth (YoY) as of 2026-07-23 | -13.6% | +63.9% | AXSM higher |
| Revenue CAGR (3y) SEC XBRL | +27.5% | +133.7% | AXSM higher |
| Beta as of 2026-07-23 | 0.86 | 0.73 | |
| 1-year return as of 2026-07-22 close | +10.6% | +116.0% | AXSM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.